Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. ...Middle East

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully...

Hence then, the article about zhimeng biopharma has completed the patients enrollment of its investigational drug cb03 154 in the pivotal phase 2 3 als clinical trial was published today ( Saturday 31/10/2026 - 08:07 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. )

Also on site :

• Ollie, a privacy-focused AI assistant, is shutting down
• Cracks are emerging in the AI spending boom
• ‘Obsession’ Director Curry Barker Pitched Nathan Fielder a Collaboration After Watching ‘You Can See Everything’: ‘I Put It Out in the Water’